Lantheus Holdings, Inc. Expense Breakdown
No Expense Breakdown for LNTH on this site yet.
- 2026-06-30: Reportable $38.20M.
- 2025-06-30: Reportable $45.49M.
Source checked: the stored Expense Breakdown page for LNTH.
Expenses by product
Research and development: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $38.20M |
| 2025-06-30 | $45.49M |
Research And Development Expense Software Excluding Acquired In Process Cost: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $8.47M |
| 2025-06-30 | $8.94M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |